India: The emerging hub for biologics and biosimilars

The global pharmaceutical industry is facing a shift from chemical-based drugs to biologics and biosimilars. While small molecule therapeutics had previously dominated research and captured major market share, the advent of large molecule therapeutics (biologics and biosimilars) has rapidly transformed the pharmaceutical industry. Given their targeted mechanism of action and reduced toxicity, biologics have gained […]

Massachusetts Law Allowing Coupons Expires on Jan 1, 2020 Unless State Acts

In Massachusetts, Drug Coupons on the Brink Drug manufacturers are concerned that, barring legislative action, drug coupons in Massachusetts will soon be forbidden. The clock is ticking for lawmakers to preserve the existing law and no signs have emerged indicating they intend to act by an end-of-the-year deadline. The existing law permits manufacturer coupons, discounts, […]

Expected blockbusters: A year in progress

Earlier this year, we released the Cortellis Drugs to Watch 2019 report, which highlighted seven drugs expected to launch in 2019 and become blockbusters in 2023. We have subsequently reported on three of those drugs that have now gained approval, including Zolgensma which entered the market as the most expensive drug ever launched. Since that […]

Digital Therapeutics Target Mental Health, Substance Use Disorders

As advancements in technology-assisted treatments evolve, digital therapeutics are emerging as a vehicle for mental health and addiction treatment. Digital therapeutics have the potential to close gaps in care for patients, reduce demands on providers’ time, and enhance the effectiveness of pharmaceuticals, offering promise for stakeholders across the spectrum of healthcare delivery.   What are […]

Never Mind Novartis’ DTxit — Digital Therapeutics is Still the Future

A Novartis subsidiary’s surprising exit last month from a closely-watched digital therapeutics partnership has prompted some soul-searching and prognosticating about the market potential of this emerging class of treatments. As my old MM&M colleague Marc Iskowitz put it in a typically thoughtful piece, “Since the Sandoz/Pear pact was widely seen as a litmus test of […]

Cell and Gene Therapies: Five Key Access and Reimbursement Strategies

Cell and gene therapies are revolutionizing the field of medicine by offering life-changing benefits to people with rare diseases and cancers. These therapies have been gaining considerable attention recently, both for addressing long-standing unmet needs and for being exceptionally pricey. As of October 2019, five cell and gene therapies have been launched in the United […]

Tenofovir alafenamide fumarate raises targeting questions

In the race to bring generic drugs to market, Paragraph IV patent challenges are now an unavoidable fact of life. The question is no longer if there will be a patent challenge, but when and by whom. In the current hypercompetitive environment, no company can pursue all possible targets, so understanding the potential competitive landscape […]

Massachusetts Enhances Ability to Negotiate Medicaid Drug Rebates

Massachusetts Enhances Ability to Negotiate Medicaid Drug Rebates Massachusetts FY 2020 Budget includes strengthened ability for the state to seek supplemental rebates from drug manufacturers for drugs purchased through MassHealth, the state’s Medicaid program. The effort could be a blueprint for other states seeking to reduce state spending on some of the highest cost drugs […]